Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dasiglucagon · 1 trial · 1 indication
Measured in minutes.
| Arm | Type | Description |
|---|---|---|
| Adult Cohort: Dasiglucagon then Glucagon | EXPERIMENTAL | Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit. |
| Adult Cohort: Glucagon then Dasiglucagon | EXPERIMENTAL | Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit. |
| Adolescent Cohort: Dasiglucagon | EXPERIMENTAL | Participants will receive a single s.c. injection of dasiglucagon. |
| Name | Type | Description |
|---|---|---|
| Dasiglucagon | DRUG | Participants will receive s.c. injection of dasiglucagon. |
| Glucagon | DRUG | Participants will receive i.m. injection of glucagon. |
Inclusion Criteria: * For Adults: Asian male or female; For Adolescents: Japanese male or female. * Age at the time of signing the informed consent: For Adults: Age 18-75 years (both inclusive): For Adolescents: Age 12-15 years (both inclusive). * Diagnosed with T1D greater than (\>)1 year befor...
Dasiglucagon is an investigational small molecule being developed for the treatment of Type 1 Diabetes Mellitus. It is designed to address very low levels of blood sugar, a condition known as hypoglycemia, in patients with this disease. The drug is currently in Phase 1 clinical development.
Dasiglucagon is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 1 Diabetes Mellitus.
Dasiglucagon is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in treating Type 1 Diabetes Mellitus.
Dasiglucagon has been studied in one completed clinical trial, identified as NCT06588504. This Phase 1 study, conducted in Japan, compared Dasiglucagon with glucagon in treating very low blood sugar in Asian adults with Type 1 Diabetes and tested Dasiglucagon in Japanese adolescents. The trial enrolled 38 participants.
Dasiglucagon is not the same as glucagon, though it is being studied in comparison to it. In a clinical trial, Dasiglucagon was compared with glucagon for treating very low blood sugar levels in patients with Type 1 Diabetes. Dasiglucagon is a separate investigational drug developed by Novo Nordisk.